Legacy Education Inc. Q4 revenue rises 40.7% to USD 19.2 million

Reuters
02/13
<a href="https://laohu8.com/S/LGCY">Legacy Education Inc.</a> Q4 revenue rises 40.7% to USD 19.2 million

Legacy Education Inc. reported revenue of USD 19.2 million for the three months ended December 31, 2025, representing a 40.7% increase driven by a 49.4% rise in new student starts to 593 and a 16.8% increase in student enrollment. Educational services expense reached USD 10.3 million for the quarter, up 37.6%, primarily due to increased instructional and staffing requirements, higher rent, externship fees, and a non-cash compensation charge. For the six months ended December 31, 2025, educational services accounted for 53.4% of revenue, general and administrative expenses represented 31.7%, and general and administrative expenses – related party were 0.5%. Net income for the six-month period was 10.7% of revenue, up by 0.5 percentage points compared to the same period in the previous year. During the period, Legacy Education Inc. highlighted the acquisition of Contra Costa Medical Career College in December 2024, expanding its portfolio of accredited academic institutions alongside High Desert Medical College, Central Coast College, and Integrity College of Health.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legacy Education Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-006392), on February 12, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10